Drug safety and the CSM
Despite the mass of pills and potions swallowed by our ancestors over the years, the perceptive and somewhat cynical physician must have realized that their effect on his patients was at best little more than useful placebos, while he played for time and invoked the healing power of Nature. The cry ringing down the centuries has been 'primum non nocere'first of all, do no harm. It is therefore understandable how intense an interest there has been in the safety of drugs in contradistinction to the level of curiosity paid to their efficacy. Even in 1964, the Committee on Safety of Drugs -the Dunlop Committee -which originated the yellow card, was almost entirely concerned with the safety of drugs and little with efficacy. Sir Derrick Dunlop, in 1967, stated that 'the Committee's remit does not impose upon it any responsibility to consider the efficacy of drugs except in so far as their safety is concerned'. In Norway and Sweden, however, there was relevant legislation dating from 1928 and 1935 which gained experience with systems to assess the efficacy of new drugs, while the Kefauver-Harris amendment to the United States Drug Law of 1962 required the pre-market submission of both efficacy and safety data to the Food and Drug Administration. In the United Kingdom it was the Medicines Act of 1968 that included efficacy as well as safety and quality as a tripartite basis for the benefit-risk judgment of new drugs. In that Act it was also laid down that the appropriate committee (Committee on Safety of Medicines -the CSM) should promote 'the collection and investigation of information relating to adverse reactions, for the purpose of enabling' it to give advice on safety, quality and efficacy of medicinal products.
From the beginning the CSM has been supported by the work of subcommittees, and in January 1982two subcommittees were fused to form SEAR, the Safety, Efficacy and Adverse Reactions Subcommittee. Then early in 1983a working party, under the chairmanship of Professor David Grahame-Smith, was established to consider the adequacy of the arrangements for monitoring adverse drug reactions in the UK. The first phase of the working party was completed by the end of1983 and approved by Ministers in March 1984 1 • A number of improvements have already been put into effect; for example, the formation of ARGOS or Adverse Reactions Group of SEAR under the chairmanship of Professor Michael Rawlins, which assists SEAR in its evaluation of adverse drug reaction (ADR) reports submitted to the CSM and helps to monitor current or potential drug safety problems. Since January 1985 there has been a monthly drug safety page in the British Medical Journal under the title of'CSM Update', a successful innovation now in its second year, and the CSM are grateful for the enthusiastic collaboration of the Editor and his staff. A pilot study has been mounted to explore the use of Viewdata equipment for reporting adverse reactions, involving around 500general practitioners including some dental practitioners, doctors in 50 hospital units and 30 pharmaceutical companies.
Discussions on ADR reporting have been held with representatives of various specialist groups, namely the British Society of Gastroenterology, the British Association for the Study of the Liver, the Association of Anaesthetists, the British Society of Haematology, the British Geriatrics Society, the British Society of Rheumatology and the Renal Association. Several of these societies have organized or have plans for organizing symposia related to drug safety at their annual meetings at which representatives of the CSM will take part. We are confident that this collaboration with the specialist disciplines will foster ADR reporting in hospital practice, where patients with the most formidable drug-induced disease are usually treated.
General practitioners are the major responders (60%) to the yellow card reporting system. Rewarding discussions have taken place with the President and officers of the Royal College of General Practitioners as well as with the chairman and members of the General Services Committee of the BMA, while numerous talks on drug safety have been given to general practitioner groups throughout the country by members of the CSM and its secretariat. The printing and mailing arrangements for communicating urgent drug safety announcements to the professions have been speeded up. Yellow cards for ADR reporting are being bound into prescription pads used by general practitioners and also into the British National Formulary supplied to all doctors in the UK. The safety, efficacy and quality of well established drugs has not been forgotten; these aspects are being carefully evaluated by the Committee on Review of Medicines under the chairmanship of Professor A W Asscher. These committees and their subcommittees are supported by a full-time professional and administrative secretariat, responsible for much of the dayto-day work on drug assessment and ADRmonitoring.
The second phase of the working party began in February 1984and the recommendations were given by the Minister of Health early in 1986 2 • Much of this report is devoted to post-marketing surveillance (PMS). Although the yellow card by itself cannot meet all the requirements of the CSM, the spontaneous reporting system based on it will need to be administered by the CSM for the foreseeable future. The UK yellow card system, which now produces 12-13000 reports annually, has made significant contributions to drug safety in the past 22 years and although not without imperfections it has many important advantages. It was also recommended that the CSM should enter into formal discussions with the ABPI on voluntary arrangements for PMS studies 0141-0768/87/ 020067-02/$02.00/0 1987 The Royal Society of Medicine 0141·0768/87/ 020068-02/$02.00/0 Cl1987 The Royal Society of Medicine on appropriate newly marketed drugs. There was no immediate prospect of improvement in the monitoring ofrare or long-latency adverse drug reactions. In the long term, it considered that record linkage systems might help and recommended that current research into this technique in the United Kingdom, already supported by the CSM, should be maintained. It was expected that there would be an increased use of prescription data in PMS studies. Representatives of the prescription pricing authority were seen and made aware of our view that requests for prescription data would certainly escalate in the future. This need could only be met by computerization to enable the identification of prescriptions relating to a considerably greater number of drugs than is possible at present. Other systems of PMS were considered, for example, cohort studies such as the prescriptionevent monitoring system developed by the drug surveillance research unit at the University of Southampton. This allows a better estimate of risks than the yellow cardbut needs significantly more time for the results to become available and is limited in the number of drugs which can be considered at anyone time, and the size of the studies which are practicable.
The part played by pharmacists in drug safety was carefully considered by the working party. It was recommended that the CSM should write to health authorities asking then to encourage the participation of pharmacists in work on adverse drug reactions in hospitals. It was appreciated that the community pharmacist wished to play some role but the working party did not consider that the pharmacists should submit ADR reports directly to the CSM. However, it suggested that a proforma might be constructed which the community pharmacist could use to refer suspected ADRs, of which he had become aware, to the patient's doctor. The confidential nature of the doctor's report to the CSM was considered to be ofthe greatest importance. The working party did not support the release of reports to pharmaceutical companies. It recommended that the CSM should follow up by personal contact with the reporting doctor most reports of serious or rare adverse drug reactions. The services of part-time medical officers could be called upon for this purpose. Representation from the Patients' Association was heard. Although the working party considered that patients should report ADRs directly to their own doctor rather than to the CSM, it agreed with the Patients' Association that more should be done to give patients accurate and readily understandable information about the medicines they use.
As the working party concluded, there is no single pointer to indicate the best way of coping with the problem of PMS and the earliest possible identification of important adverse drug reactions. The way forward might well be on a broad front representing a pragmatic approach, using every relevant technological aid and, above all, relying on the clinical acumen and level of awareness of the practising doctor. Nothing at present can replace the voluntary system for reporting, be it by letters to editors or to manufacturers or the filling out of various forms for national reporting schemes, such as the yellow card. It was encouraging to read Louis Lasagna 3 , the distinguished American expert on drug safety, giving his strong support to the voluntary system of reporting and in particular the yellow card system in the United Kingdom. The CSM is grateful for the initiative taken by the former editor of this journal (Dr Victor Bloom) who organized a meeting in April 1984with medical editors at the RSM. As a result, many more medical editors advise authors of papers on ADRs to report their findings in the first instance to the CSM. There is now far greater communication between the CSM, the medical profession and the medical journals, which augurs well for the early identification and rapid resolution of any future problems.
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Tenosynovitis
The definition of this disorder has become somewhat blurred, particularly in lay and medicolegal parlance. Tenosynovitis can occur in both upper and lower limbs. In the latter it mainly affects the peroneal and posterotibial compartment tendons.
Upper limb tenosynovitis has been lumped together with tendinitis, paratendinitis, peritendinitis crepitans, triggering fingers, stenosing tenovaginitis (de Quervains), repetitive strain injury, carpal tunnel syndrome, epicondylitis (tennis and golfers elbow) and brachial neuralgia, all of which produce 'arm pain'. These disorders are distinct and have specific symptoms and signs and differing aetiologies and management. Strictly speaking, tenosynovitis can only occur where a tendon is invested by a synovial sheath such as the finger flexors. The term has been devalued by loose usage and in particular is confused with paratendinitis, especially on the dorsum of the hand where the extensors have no synovial sheath except in relation to the retinaculum at wrist level.
There are numerous aetiologies for tenosynovitis. Infection with a large variety of organisms has been described. Synovial inflammation can occur in very many connective tissue diseases, most commonly in rheumatoid disease. Traumatic tenosynovitis can occur after a single injury which damages the synovial lining or by an effusion of blood into the
